Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Hallberg

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|October 14, 2005
Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinityJennie Georgsson, Christian Sköld, Bianca Plouffe, et al.
Journal of Hypertension|August 15, 2009
Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damagePaolo Gelosa, Alice Pignieri, Lars Fändriks, et al.
Journal of Medicinal Chemistry|June 10, 2005
New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonistsUlrika Rosenström, Christian Sköld, Bianca Plouffe, et al.
Journal of Medicinal Chemistry|September 16, 2005
Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulationsKarolina Ersmark, Martin Nervall, Elizabeth Hamelink, et al.
European Journal of Biochemistry|November 25, 2004
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacyJimmy Lindberg, David Pyring, Seved Löwgren, et al.
Pharmacological Reviews|September 30, 2022
The Angiotensin AT<sub>2</sub> Receptor: From a Binding Site to a Novel Therapeutic TargetU Muscha Steckelings, Robert E Widdop, Edward D Sturrock, et al.
Clinical Science (London, England : 1979)|October 21, 2014
Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaisonDaniel Villela, Julia Leonhardt, Neal Patel, et al.
Hypertension (Dallas, Tex. : 1979)|January 1, 2014
Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heartDilyara Lauer, Svetlana Slavic, Manuela Sommerfeld, et al.
Journal of Medicinal Chemistry|June 11, 2004
Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifsPer-Ola Johansson, Yantao Chen, Anna Karin Belfrage, et al.
Biochemical Pharmacology|September 9, 2023
Functional assay for assessment of agonistic or antagonistic activity of angiotensin AT<sub>2</sub> receptor ligands reveals that EMA401 and PD123319 have agonistic propertiesA Augusto Peluso, Igor M Souza-Silva, Daniel C Villela, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|October 14, 2005
Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinityJennie Georgsson, Christian Sköld, Bianca Plouffe, et al.
Journal of Hypertension|August 15, 2009
Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damagePaolo Gelosa, Alice Pignieri, Lars Fändriks, et al.
Journal of Medicinal Chemistry|June 10, 2005
New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonistsUlrika Rosenström, Christian Sköld, Bianca Plouffe, et al.
Journal of Medicinal Chemistry|September 16, 2005
Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulationsKarolina Ersmark, Martin Nervall, Elizabeth Hamelink, et al.
European Journal of Biochemistry|November 25, 2004
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacyJimmy Lindberg, David Pyring, Seved Löwgren, et al.
Pharmacological Reviews|September 30, 2022
The Angiotensin AT<sub>2</sub> Receptor: From a Binding Site to a Novel Therapeutic TargetU Muscha Steckelings, Robert E Widdop, Edward D Sturrock, et al.
Clinical Science (London, England : 1979)|October 21, 2014
Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaisonDaniel Villela, Julia Leonhardt, Neal Patel, et al.
Hypertension (Dallas, Tex. : 1979)|January 1, 2014
Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heartDilyara Lauer, Svetlana Slavic, Manuela Sommerfeld, et al.
Journal of Medicinal Chemistry|June 11, 2004
Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifsPer-Ola Johansson, Yantao Chen, Anna Karin Belfrage, et al.
Biochemical Pharmacology|September 9, 2023
Functional assay for assessment of agonistic or antagonistic activity of angiotensin AT<sub>2</sub> receptor ligands reveals that EMA401 and PD123319 have agonistic propertiesA Augusto Peluso, Igor M Souza-Silva, Daniel C Villela, et al.
Pageof 11